Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva To Invest Billion In India Acquisitions, New Facility

This article was originally published in PharmAsia News

Executive Summary

Teva Pharmaceutical Industries of Israel says it plans to spend more than $1 billion in India, about three-fourths of the amount in buying Indian drug makers. The company said it expects to spend $250 million to $300 million on building manufacturing facilities in India, mainly for active pharmaceutical ingredient work. Teva already is the world's largest producer of generic drugs and launched Teva India as its India-based research and development center two years ago. Teva is reported to have been eyeing a major acquisition in India for several years, and possible targets include Aurobindo, Cipla, Matrix, Orchid and Saraca Laboratories. (Click here for more

You may also be interested in...

Teva To Expand Presence In India

LUCKNOW, UTTAR PRADESH, INDIA - Israeli pharmaceutical company Teva Pharmaceutical will invest more than $1 billion in India over the next two years to establish greenfield manufacturing facilities and acquire Indian drug companies, said a Jan. 10 report in the local newspaper Business Standard.

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts